-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-11-09
Values as of: 2024-11-09
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the health care equipment and supplies segment of a U.S. total market composite index. In seeking to track the performance of the S&P Health Care Equipment Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the health care equipment segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 26/01/2011
Primary Benchmark: S&P HealthCare Equip Sel Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| ATEC | Alphatec Holdings Inc | 2.56 % |
| IART | Integra LifeSciences Holdings | 2.52 % |
| MASI | Masimo Corporation | 2.47 % |
| ATRC | AtriCure Inc | 2.28 % |
| PEN | Penumbra Inc | 2.15 % |
| OMCL | Omnicell Inc | 2.09 % |
| PRCT | Procept Biorobotics Corp | 2.04 % |
| GMED | Globus Medical | 2.03 % |
| IRTC | iRhythm Technologies Inc | 1.99 % |
| HAE | Haemonetics Corporation | 1.96 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
-2.08 (-1.39%) |
USD 40.46B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-1.03 (-1.45%) |
USD 2.91B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
-1.57 (-1.39%) |
USD 1.19B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
-0.82 (-3.19%) |
USD 0.15B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
-1.67 (-3.93%) |
USD 0.13B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
-1.54 (-1.56%) |
USD 0.08B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
-0.45 (-1.48%) |
USD 0.06B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-2.05 (-3.02%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
-1.51 (-4.81%) |
USD 0.01B |
| IHE | iShares U.S. Pharmaceuticals E.. | 0.42 % |
-1.00 (-1.42%) |
N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| INAV | 0.00 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -45.06% | 38% | F | 11% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -45.06% | 38% | F | 12% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -31.53% | 43% | F | 12% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -31.53% | 43% | F | 14% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -42.93% | 29% | F | 17% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -42.93% | 29% | F | 18% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 0.30% | 29% | F | 34% | F | ||
| Dividend Return | 0.31% | 29% | F | 24% | F | ||
| Total Return | 0.01% | 5% | F | 1% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 26.68% | 33% | F | 41% | F | ||
| Risk Adjusted Return | 1.17% | 29% | F | 22% | F | ||
| Market Capitalization | 0.07B | 70% | C- | 37% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
